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Bacterial pneumonia with empyema is a serious com-
plication of inﬂ  uenza and commonly resulted in death dur-
ing the 1918 inﬂ   uenza pandemic. We hypothesize that 
deaths caused by parapneumonic empyema are increasing 
in Utah once again despite advances in critical care and 
the availability of antimicrobial drugs and new vaccines. In 
this study, we analyzed the historical relationship between 
deaths caused by empyema and inﬂ  uenza pandemics by 
using 100 years of data from Utah. Deaths caused by em-
pyema have indeed increased from 2000–2004 when com-
pared with the historic low death rates of 1950–1975. Vac-
cine strategies and antimicrobial drug stockpiling to control 
empyema will be important as we prepare for the next inﬂ  u-
enza pandemic.
A
n inﬂ  uenza pandemic is thought to be the most likely 
and most severe biological emergency facing the Unit-
ed States (1–3). Bacterial pneumonia is a serious complica-
tion of inﬂ  uenza infection and was likely a major cause of 
the excess deaths seen during the 1918 inﬂ  uenza pandemic 
(4–8). Even today, though the overall disease mortality rate 
due to infectious diseases is declining in the United States, 
death from pneumonia and inﬂ  uenza remains one of the top 
10 causes of death overall (9,10). 
Parapneumonic empyema, a serious complication 
of bacterial pneumonia frequently caused by Streptococ-
cus pneumonia and Staphylococcus aureus, is increasing 
in North and South America, Europe, and Asia (11–21). 
As we prepare for an inﬂ  uenza pandemic, changes in the 
microbiology of pneumonia and the increasing rates of em-
pyema must be considered. In this study, we analyzed the 
historical relationship between deaths due to empyema and 
inﬂ  uenza pandemics using 100 years of data from Utah. 
Methods
Utah Population Database
The Utah Population Database (UPDB) is a computer-
ized genealogical database linking multiple data sources. 
The resource includes genealogical records of the original 
Utah pioneers (members of the Church of Jesus Christ of 
Latter Day Saints) who settled in Utah in 1847 and their de-
scendants. These records have been linked to disease data 
for Utah, including death certiﬁ  cate records dating back to 
1904. We used a version of the database without individual 
identiﬁ  ers that spans 100 years (1904–2004). 
Identiﬁ  cation of Patients
The institutional review boards for both the University 
of Utah and the UPDB reviewed and approved this study. 
Each death record in the UPDB contains a primary cause 
of death that was coded with the International Classiﬁ  ca-
tion of Diseases (ICD) nomenclature. All death certiﬁ  cates 
between 1956 and 2004 were encoded by using ICD re-
visions 6 through 10. For death certiﬁ   cates from 1904 
through 1955, a nosologist with a University of Utah re-
search project used the literal information and coded cause 
of death to ICD revision 10 using the 2000 Medical Data 
System and supplemented this system with hand coding. 
During 1985–1995, the Bureau of Vital Statistics added 
selected secondary causes of death, including pneumonia, 
empyema, and inﬂ  uenza. Beginning in 1996, death certiﬁ  -
cate records contained multiple secondary causes of death 
and classiﬁ  ed persons with each. We searched the UPDB 
for deaths associated with empyema on the basis of ICD 
Parapneumonic Empyema Deaths 
during Past Century, Utah
Jeffrey M. Bender, Krow Ampofo, Xiaoming Sheng, Andrew T. Pavia, Lisa Cannon-Albright, 
and Carrie L. Byington
HISTORICAL REVIEW
44  Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 15, No. 1, January 2009
Author afﬁ  liation: University of Utah School of Medicine, Salt Lake 
City, Utah, USA
DOI:  10.3201/eid1501.080618Parapneumonic Empyema Deaths, Utah
codes: ICD-10 J869, ICD-9 510.9, ICD-8 510, ICD-7 518, 
and ICD-6 518. For inﬂ  uenza deaths, we used the following 
ICD codes: ICD-10 J10, J11, ICD-9 487, ICD-8 470–474, 
ICD-7 480–483, and ICD-6 480–483. 
Statistical Analysis
We analyzed empyema-related deaths by decade and 
population to examine trends in death related to empyema. 
We analyzed empyema deaths in 2 age groups: children 
(0–18 years of age) and adults (>18 years of age). Utah 
population was determined based on national census data. 
Utah’s population data have been available every 10 years 
from 1900 through 2000 and for 2005. Using available data, 
we ﬁ  tted a cubic curve of log-transformed population for 
1 year to estimate Utah’s population for other years. We 
deﬁ  ned 3 notable periods in Utah history. Period 1, 1917–
1920, represents the Spanish inﬂ  uenza pandemic. Period 2, 
1950–1975, represents the post–antimicrobial drug era and 
encompasses smaller inﬂ  uenza pandemic periods of 1957–
58 and 1968–69. Period 3, 2000–2004, includes the period 
of increasing incidence of empyema in children (15,22) and 
recent increases in empyema deaths. A Poisson model was 
used to estimate risk for death in different years and com-
pare estimates among the 3 identiﬁ  ed periods.
Results
Empyema and inﬂ  uenza death rates in Utah over a 
100-year period are shown in the Figure. A high rate of 
deaths caused by empyema occurred during 1900–1909. 
Deaths caused by empyema peaked at 18/10,000 person-
years during the decade 1910–1919, which included the 
1918–19 Spanish inﬂ  uenza pandemic (period 1). Empyema 
deaths steadily decreased in the decades after the Spanish 
inﬂ  uenza pandemic. This decline is most apparent in the 
1930s, coincident with the widespread introduction of sul-
fonamide antibiotics. With the introduction of penicillin 
during World War II, deaths caused by empyema leveled 
off substantially in the 1940s–1950s. During the period 
from 1950 through 1975 (period 2), empyema deaths re-
mained at a nadir of 0.4–0.8/10,000 person-years. The rate 
of deaths increased signiﬁ  cantly during the ﬁ  nal 5-year pe-
riod from 2000–2004 (period 3). Compared with period 2, 
the death rate for persons with empyema in Utah during 
period 3 was 3.2/10,000 person years, >6-fold higher (rate 
ratio 6.6; 95% conﬁ  dence interval 3.2–13.4: p<0.005). 
During the pre–antimicrobial drug era and during the 
1918–19 inﬂ  uenza pandemic, children 0–18 years of age 
accounted for 31%–37% of all empyema deaths. Between 
1940 and 1999, deaths among children decreased more dra-
matically than among adults and accounted for <4% of all 
empyema deaths. Almost all (97%) of the empyema deaths 
seen recently in period 3 are in adults >18 years of age, 
most among persons >65 years of age. 
Death rates attributed to inﬂ  uenza peaked dramatically 
during the decade 1910–1919, associated with the peak 
in empyema deaths. After 1970, the number of inﬂ  uenza 
deaths declined steadily and has remained very low. 
Discussion
The rates of empyema leading to death in Utah have 
signiﬁ  cantly increased between 2000–2004. This increase 
occurred in the absence of a major inﬂ  uenza pandemic and 
in spite of advances in medical care. The recent increase in 
empyema deaths is unexplained and may have broad impli-
cations for future inﬂ  uenza pandemics. 
Empyema caused substantial illness and death in the 
era before antibiotics. In the 8th edition of his book, pub-
lished just before the Spanish inﬂ  uenza pandemic, Osler 
described empyema as “a most common complication [of 
pneumonia] occurring in 2.2 percent of clinical cases” seen 
over an 8-year period at Johns Hopkins Hospital (22). He 
described pneumococcus as the most common pathogen 
leading to empyema. Pneumonia and empyema were, at 
the time, “the most fatal of all acute diseases” (22). Osler 
himself died of pneumonia and empyema in 1919. 
Inﬂ  uenza has historically been linked to pneumonia 
deaths. According to our study, deaths caused by empyema 
peaked during the Spanish inﬂ  uenza pandemic of 1918–19. 
The estimated worldwide death toll attributed to Spanish 
inﬂ  uenza has been estimated at 21–50 million (23). Pneu-
monia, especially due to S. pneumoniae, is thought to be a 
major contributor to the excess deaths seen during the 1918 
inﬂ  uenza pandemic (5,6). As seen in the Figure, data from 
the UPDB demonstrate an increase in deaths caused by 
empyema during this period, although it is not as dramatic 
as the increase in deaths attributed to inﬂ  uenza. This ﬁ  nd-
ing suggests that empyema contributed to the deaths from 
pneumonia associated with the inﬂ  uenza pandemic. 
The number of deaths due to empyema fell moder-
ately during the decades of the 1920s and 1930s but fell 
dramatically after 1940 and World War II. This decrease in 
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Figure. Average rates of deaths in Utah caused by parapneumonic 
empyema and inﬂ  uenza, by decade, 1900–2005.HISTORICAL REVIEW
empyema deaths corresponds with the beginning of the an-
timicrobial drug era. During the 1950s and 1960s, when the 
pandemics of 1957 and 1968 occurred, the rate of deaths 
caused by empyema remained low. We did not observe a 
signiﬁ  cant increase in the deaths caused by inﬂ  uenza over 
the same period. This lack of an increase may have been due 
to the relatively mild nature of these pandemics compared 
with the 1918 pandemic, the availability of antimicrobial 
drugs, improvements in the management of pneumonia and 
its complications, and perhaps the insensitivity inherent in 
examining death rates by decade. 
We noted a statistically signiﬁ  cant increase in the num-
ber of empyema deaths in Utah at the turn of the 21st centu-
ry (2000–2004) when compared with the mid-20th century 
(1950–1975). This increase in empyema deaths has taken 
place without the advent of an inﬂ  uenza pandemic and in 
the setting of continued advances in medical care. The in-
crease in death rates/person years caused by empyema is 
primarily seen in the adult population and is most apparent 
in patients >65 years of age. What might account for this 
increase in empyema deaths? We speculate that increased 
mortality rates from empyema are caused by changes in the 
organisms that cause pneumonia and empyema worldwide. 
S. pneumoniae is thought to have been the major cause 
of death from secondary bacteria in prior pandemic inﬂ  u-
enza outbreaks. Comparing all 3 of the inﬂ  uenza pandem-
ics of the twentieth century, 1 study estimates that 50% of 
bacterial pneumonia cases associated with inﬂ  uenza were 
caused by S. pneumoniae (24). Experimental as well as epi-
demiologic data support the association between serious S. 
pneumoniae infections and inﬂ  uenza. Studies by McCull-
ers and others have shown that inﬂ  uenza virus infection 
preferentially predisposes mice to fatal infections with S. 
pneumoniae (25–27). Recent studies have demonstrated a 
clear temporal association between seasonal inﬂ  uenza and 
invasive pneumococcal disease in children (28). 
Changes in circulating serotypes of S. pneumo-
niae have been reported from many regions worldwide 
(11,14,16,17,29–32). These changes may play a role in the 
increase in deaths caused by empyema. The annual inci-
dence of invasive disease caused by S. pneumoniae has de-
creased signiﬁ  cantly in all age groups with the introduction 
of the 7-valent pneumococcal conjugate vaccine (PCV-7) 
in 2000 (33). Further, disease caused by resistant S. pneu-
moniae has also decreased signiﬁ  cantly with the introduc-
tion of the PCV-7 vaccine, which targeted the resistant 
serotypes (33,34). Thus, antimicrobial drug resistance to 
S. pneumoniae seems unlikely to be responsible for the in-
crease in empyema deaths since the introduction of PCV-7. 
In spite of the recent decreases in invasive pneumococcal 
disease, hospitalizations for empyema are increasing in US 
children (20). Recent reports further show that the incidence 
of empyema due to non–PCV-7 serotypes, especially types 
1, 3, and 19A, has increased signiﬁ  cantly worldwide in the 
post PCV-7 era (11–17,21,32). These serotypes are histori-
cally associated with severe invasive disease, particularly 
empyema, and might contribute to the increased rates of 
deaths caused by empyema among adults (17,35,36). 
S. aureus is increasingly recognized as a signiﬁ  cant 
cause of complicated pneumonia. A recent study from 
France demonstrated a mortality rate of >50% in patients 
infected with S. aureus that contained Panton-Valentine 
leukocidin (PVL), which caused necrotizing pneumonia 
(37). A study among children from Houston demonstrated 
a marked increase in complicated pneumonia in patients 
with PVL-containing S. aureus infection (29). The PVL 
gene is now considered one of the identifying features 
of community-associated methicillin-resistant S. aureus 
(CA-MRSA) and is at least a marker for invasiveness and 
virulence, although the exact contribution of PVL remains 
unclear (38). 
CA-MRSA has become more widespread over the past 
decade and has been responsible for increasing amounts 
of severe complicated pneumonias in the community (19). 
The Centers for Disease Control and Prevention reported 
a signiﬁ  cant increase in CA-MRSA pneumonia associated 
with inﬂ  uenza infection in the United States during 2006–
2007, including deaths among previously healthy children 
(18). 
History reminds us that we must be prepared to deal 
with severe bacterial pneumonia when planning for future 
inﬂ  uenza threats. Good evidence exists that inﬂ  uenza will 
interact with bacterial pathogens to cause severe pneumo-
nia and increased mortality rates. Thus, the recent increase 
in deaths caused by empyema has potential implications 
for pandemic inﬂ  uenza preparedness. The rise of pneumo-
coccal serotypes with a propensity to cause complicated 
pneumonia and increasing rates of community acquired 
pneumonias due to CA-MRSA should be considered 
when developing strategies to prevent and treat inﬂ  uenza 
complications. These strategies might include broadening 
recommendations for existing or enhanced pneumococcal 
vaccines that cover serotypes associated with empyema, 
such as 1, 3, and 19A. Determining who should be vacci-
nated with these pneumococcal vaccines during an inﬂ  u-
enza pandemic would have to be done on the basis of risk 
and the availability of vaccines. Further, the stockpiling 
of antimicrobial drugs active against CA-MRSA and oth-
er resistant pathogens may also be needed. Currently, the 
US Department of Health and Human Services Pandemic 
Inﬂ  uenza Plan from 2005 does not speciﬁ  cally account 
for secondary bacterial infections or the need for bacterial 
vaccines (1,39). 
However, the Infectious Diseases Society of America 
called for improved antibacterial agents and vaccines as a 
key need in pandemic inﬂ  uenza preparedness (40). Our data 
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provide support for this concept. Extending the range of 
conjugate pneumococcal vaccines to include the serotypes 
now commonly associated with empyema and encouraging 
broader use of the polysaccharide vaccine may help lessen 
the effects of S. pneumoniae infection on a pandemic. If high 
vaccination rates cannot be routinely achieved, stockpiles 
of pneumococcal vaccine might be needed. Antimicrobial 
drug stockpiling, particularly agents with activity against 
MRSA, should be included in the discussion of antiviral 
drug stockpiling as well. Further, because the treatment for 
empyema frequently requires drainage either through chest 
tubes or surgical procedures, planning for these healthcare 
resources should also be considered. 
This study has some limitations. Cause of death in 
death certiﬁ  cate data is not always accurate, and the ac-
curacy may vary by disease. The clinical manifestations 
of empyema were well described by 1900 (22). Empyema 
was common during the pre–antimicrobial drug era and 
relatively easy to document with clinical examination and 
chest radiographs. Thus, it seems unlikely that recognition 
or reporting of empyema changed with time during the pe-
riod covered in this historical study. There is no reason to 
suspect that empyema was more readily diagnosed in the 
ﬁ  nal 5 years of the study, that deﬁ  nitions changed, or that 
it was more readily listed as a cause of death. Inﬂ  uenza, in 
contrast, is more difﬁ  cult to diagnose clinically and may 
have been more readily listed as a cause of death during 
known pandemics and after virologic testing became avail-
able. Our data do not include microbiology results, so the 
association between empyema deaths and speciﬁ  c organ-
isms is speculative.
We observed a signiﬁ  cant increase in deaths caused 
by bacterial empyema during the period of the inﬂ  uenza 
pandemic of 1918–19 and an unexplained increase from 
2000 through 2005. As secondary bacterial pneumonia his-
torically has been a signiﬁ  cant cause of illness and death 
in inﬂ  uenza pandemics, understanding the recent increase 
in empyema deaths is critical as we prepare for the next 
inﬂ  uenza pandemic. Changes in prevalent bacteria, includ-
ing S. pneumoniae serotypes and the virulence of S. au-
reus, should be further explored. Pneumococcal vaccines 
targeting the serotypes most associated with empyema and 
antimicrobial agents against resistant bacteria such as CA-
MRSA should be key components in national and interna-
tional inﬂ  uenza pandemic planning. 
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